Market closed
Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Ticker
$EOLS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
332
Website
Evolus Metrics
BasicAdvanced
$853M
-
-$0.81
1.28
-
Price and volume
Market cap
$853M
Beta
1.28
52-week high
$17.12
52-week low
$9.25
Average daily volume
796K
Financial strength
Current ratio
2.404
Quick ratio
2.138
Long term debt to equity
2,200.398
Total debt to equity
2,200.398
Interest coverage (TTM)
-1.45%
Management effectiveness
Return on assets (TTM)
-8.08%
Return on equity (TTM)
664.86%
Valuation
Price to revenue (TTM)
3.126
Price to book
150.72
Price to tangible book (TTM)
150.72
Price to free cash flow (TTM)
-46.24
Growth
Revenue change (TTM)
31.76%
Earnings per share change (TTM)
-24.98%
3-year revenue growth (CAGR)
38.76%
3-year earnings per share growth (CAGR)
-4.74%
What the Analysts think about Evolus
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Evolus Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Evolus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Evolus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $853M as of March 14, 2025.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of March 14, 2025.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.